Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.

@article{Wishart1994QuinidineAA,
  title={Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.},
  author={Gordon C. Wishart and Donald Bissett and James Paul and Duncan J. Jodrell and Alison Harnett and Timothy Habeshaw and David James Kerr and M. A. Macham and Michael Soukop and Robert C. F. Leonard},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 9},
  pages={1771-7}
}
PURPOSE To evaluate the effect of quinidine, a putative modulator of P-glycoprotein-mediated drug resistance, on the response rate and toxicity profile of epirubicin in patients with advanced breast cancer. PATIENTS AND METHODS Between 1989 and 1992, 223 eligible patients were randomized in double-blind fashion to receive epirubicin 100 mg/m2 by intravenous (i.v.) bolus and prednisolone 25 mg orally twice daily, along with either placebo or quinidine (250 mg) capsules, taken for 4 days before… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Similar Papers

Loading similar papers…